Cerulea Clinical Trials

Science and Research

DRAGON study

This study will explore the safety and efficacy of oral tinlarebant tablets as compared to oral placebo tablets, in slowing down disease progression, or the changes to the retina, in people with Stargardt disease. This trial is operated by the Centre for Eye Research Australia.

Overview

This study will explore the safety and efficacy of oral tinlarebant tablets as compared to oral placebo tablets, in slowing down disease progression, or the changes to the retina, in people with Stargardt disease. This study is involving people aged 12 to 20 years, before significant vision loss and retinal degeneration has occurred.

This study will follow up participants for 2 years and measure the size and pattern of disease using various retinal imaging modalities. Additionally, a range of visual function assessments will be performed.

  • Principal Investigator
Dr Thomas Edwards

Learn more

View this study at ClinicalTrials.gov

This database listing provides more detailed information about this study.